Hematologic Malignancy
High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements
CI-CAN-00009268DHLExplore in graph →
Hematologic21 active trials
- NCIt
- C125904
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009268DHLExplore in graph →
Clinical trials
31 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06649812 | Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma | recruiting | Phase 2 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03418038 | Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia | recruiting | Phase 2 | 80 | Mayo ClinicOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05600686 | Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma | active not recruiting | Phase 2 | 24 | University of California, DavisOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06536049 | Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 38 | Yazeed SawalhaOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07724457 | Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma | not yet recruiting | Phase 2 / Phase 3 | 271 | National Cancer Institute (NCI)NIH | 0 | Aug 19, 2026 | clinicaltrials |
| NCT07649304 | AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") | not yet recruiting | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 0 | Aug 13, 2026 | clinicaltrials |
| NCT03136146 | Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia | recruiting | Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT03984448 | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas | active not recruiting | Phase 2 / Phase 3 | 363 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 | clinicaltrials |
| NCT02727803 | Personalized NK Cell Therapy in CBT | recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05821088 | Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma | active not recruiting | Phase 2 | 37 | David Bond, MDOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT04799275 | Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma | active not recruiting | Phase 2 / Phase 3 | 422 | National Cancer Institute (NCI)NIH | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06905509 | Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | recruiting | Phase 2 | 25 | University of California, DavisOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT03038672 | Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas | active not recruiting | Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | May 12, 2026 | clinicaltrials |
| NCT07552324 | Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP | not yet recruiting | Phase 2 | 28 | Ruijin HospitalOTHER | 0 | Apr 27, 2026 | clinicaltrials |
| NCT05507541 | TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | active not recruiting | Phase 2 | 10 | Mayo ClinicOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07042438 | Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells | recruiting | Phase 2 | 56 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05755087 | Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma | recruiting | Phase 1 | 18 | Lapo AlinariOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04323956 | Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma | active not recruiting | Phase 1 | 50 | Mayo ClinicOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04285268 | Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | withdrawn | Phase 2 | 0 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT06834373 | Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy | recruiting | Phase 2 | 41 | Mayo ClinicOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06588205 | Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma(FIL_MIMYC) | recruiting | — | 200 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT05908409 | A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies(CASSANDRA) | recruiting | Phase 1 / Phase 2 | 37 | IDP Discovery Pharma S.L.INDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT06287398 | Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL | recruiting | Phase 2 | 39 | Australasian Leukaemia and Lymphoma GroupOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT02199184 | Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2024 | clinicaltrials |
| NCT03103971 | huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | terminated | Phase 1 | 55 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT05974085 | XPO-1 in Combination With RCHOP for DH/TH Lymphoma | unknown | Phase 2 | 10 | Zhejiang Cancer HospitalOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05228249 | Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT03629873 | Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects | unknown | Phase 2 | 69 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT01742988 | Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma | completed | Phase 1 | 106 | Curis, Inc.INDUSTRY | 1 | May 6, 2021 | clinicaltrials |
| NCT01619761 | NK Cells in Cord Blood Transplantation | unknown | Phase 1 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT01897012 | Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas | completed | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Jan 28, 2019 | clinicaltrials |
Data updated 17 hours agoSource updated Sep 29, 2026source: clinicaltrials